Tips from Other Journals

What Is the Best Treatment for Childhood Absence Epilepsy?

Am Fam Physician. 2011 Jan 1;83(1):81-82.

Background: Childhood absence epilepsy is the most common form of epilepsy in children. Ethosuximide (Zarontin), lamotrigine (Lamictal), and valproic acid (Depakote) are options for initial monotherapy, but their relative effectiveness and tolerabilities have not been determined. Glauser and colleagues conducted a double-blind, randomized controlled trial to assess for these effects and determine the optimal therapy for childhood absence epilepsy.

The Study: The authors enrolled 453 children 2.5 to 13 years of age who were newly diagnosed with childhood absence epilepsy. Patients received ethosuximide (maximal dosage: 60 mg per kg or 2,000 mg per day), lamotrigine (maximal dosage: 12 mg per kg or 600 mg per day), or valproic acid (maximal dosage: 60 mg per kg or 3,000 mg per day). Medications could be titrated upward for persistent seizures, up to the maximal allowed dosages. The primary outcome was freedom from treatment failure after 16 to 20 weeks; treatment failure was defined as persistent absence seizures, generalized tonicclonic seizures, or drug-related systemic toxicity. Attentional dysfunction was the secondary outcome, measured by neuropsychological testing at baseline and at the conclusion of the study.

Patients were excluded if they had a history of other types of seizures, severe rashes with any medication, a major psychiatric disease, an autism spectrum disorder, abnormal liver enzymes or complete blood count, or any other clinically significant medical conditions.

Results: Baseline characteristics were similar among the groups, with a median age of seven years, five months. Overall, 47 percent of the patients were free from treatment failure at the end of the study. Patients taking ethosuximide or valproic acid were less likely to experience treatment failure (47 and 42 percent, respectively) compared with those taking lamotrigine (71 percent). More patients were seizure-free with ethosuximide and valproic acid than with lamotrigine (see accompanying table). However, valproic acid was associated with more attentional dysfunction than ethosuximide or lamotrigine.

Table.

Relative Effectiveness and Safety of Agents for Childhood Absence Epilepsy Seizures

Agent Odds ratio of controlling seizures without drug toxicity Odds ratio of having persistent seizures Odds ratio of attentional dysfunction

Ethosuximide (Zarontin; versus lamotrigine [Lamictal])

2.66

0.19

1.56 (NS)

Valproic acid (Depakote; versus lamotrigine)

3.34

0.16

3.04

Valproic acid (versus ethosuximide)

1.26 (NS)

0.84 (NS)

1.95


note: All odds ratios are significant unless otherwise noted..

NS = not significant

Table.   Relative Effectiveness and Safety of Agents for Childhood Absence Epilepsy Seizures

View Table

Table.

Relative Effectiveness and Safety of Agents for Childhood Absence Epilepsy Seizures

Agent Odds ratio of controlling seizures without drug toxicity Odds ratio of having persistent seizures Odds ratio of attentional dysfunction

Ethosuximide (Zarontin; versus lamotrigine [Lamictal])

2.66

0.19

1.56 (NS)

Valproic acid (Depakote; versus lamotrigine)

3.34

0.16

3.04

Valproic acid (versus ethosuximide)

1.26 (NS)

0.84 (NS)

1.95


note: All odds ratios are significant unless otherwise noted..

NS = not significant

Conclusion: The authors conclude that ethosuximide and valproic acid are more effective than lamotrigine in controlling seizures associated with childhood absence epilepsy. However, valproic acid is associated with greater attentional dysfunction, indicating that ethosuximide is the more appropriate initial therapy for this seizure disorder.

Source

Glauser TA, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. March 4, 2010;362(9):790–799.


Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article